FDA-approved epilepsy drug may help reverse osteoarthritis damage

AI Insight

Yale researchers have discovered that lacosamide, an FDA-approved epilepsy medication, may address osteoarthritis by targeting a protein involved in both pain signaling and cartilage destruction. In preclinical studies, the drug appeared to not only reduce pain but also help damaged joints shift toward a repair state, suggesting a potential disease-modifying effect rather than symptom management alone.

Why it matters

Current osteoarthritis treatments primarily focus on pain relief without reversing joint damage. If these findings translate to human patients, lacosamide could offer the first therapeutic approach that actively promotes cartilage repair while simultaneously managing pain, potentially delaying or preventing the need for joint replacement surgery.